Omeros (NASDAQ:OMER) Earns “Overweight” Rating from Cantor Fitzgerald

Omeros (NASDAQ:OMER)‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. They presently have a $22.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 19.37% from the company’s current price.

Several other equities analysts have also weighed in on OMER. Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, HC Wainwright restated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Three investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $30.33.

Omeros Price Performance

Shares of NASDAQ OMER opened at $18.43 on Wednesday. The company’s 50 day simple moving average is $18.24 and its 200 day simple moving average is $13.78. Omeros has a fifty-two week low of $6.24 and a fifty-two week high of $21.24. The firm has a market capitalization of $1.33 billion, a P/E ratio of 6.92 and a beta of 2.57.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. Sell-side analysts expect that Omeros will post -0.37 EPS for the current fiscal year.

Insider Activity

In other Omeros news, VP Peter B. Cancelmo sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the sale, the vice president owned 200 shares of the company’s stock, valued at approximately $3,708. This represents a 99.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO David J. Borges sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $20.95, for a total transaction of $209,500.00. Following the completion of the sale, the chief accounting officer directly owned 5,000 shares of the company’s stock, valued at $104,750. The trade was a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,906 shares of company stock worth $1,989,705 over the last three months. Company insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On Omeros

Large investors have recently bought and sold shares of the company. GK Wealth Management LLC bought a new stake in shares of Omeros during the third quarter worth $65,000. State Street Corp increased its position in shares of Omeros by 20.9% during the second quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company’s stock worth $22,062,000 after acquiring an additional 400,331 shares in the last quarter. Engineers Gate Manager LP bought a new stake in shares of Omeros during the second quarter worth $138,000. Squarepoint Ops LLC bought a new stake in shares of Omeros during the second quarter worth $523,000. Finally, Arizona State Retirement System bought a new stake in shares of Omeros during the second quarter worth $179,000. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.